Edoxaban vs. vitamin K antagonist for atrial fibrillation after transcatheter aortic valve replacement in Japanese patients – A subanalysis of the ENVISAGE-TAVI AF trial.

ホーム
論文
Edoxaban vs. vitamin K antagonist for atrial fibrillation after transcatheter aortic valve replacement in Japanese patients - A subanalysis of the ENVISAGE-TAVI AF trial.

Edoxaban vs. vitamin K antagonist for atrial fibrillation after transcatheter aortic valve replacement in Japanese patients - A subanalysis of the ENVISAGE-TAVI AF trial.

2022.07.18

雑誌：Circulation Journal, 2022;86(11)：1756-1763.

著者：Watanabe Yusuke, Hayashida Kentaro, Yamamoto Masanori, Yamanaka Futoshi, Yamasaki Kazumasa, Naganuma Toru, Ohno Yohei, Yamawaki Masahiro, Morioka Nobuyuki, Mizutani Kazuki, Tada Norio, Ueno Hiroshi, Nishina Hidetaka, Izumo Masaki, Nakajima Yoshifumi, Ando Kenji, Takagi Kensuke, Kimura Tetsuya, Sugio Kumiko, Dangas George, Van Mieghem Nicolas M, Hengstenberg Christian, Chen Cathy, Jin James, Unverdorben Martin, Saito Shigeru.